Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study

Trial Profile

Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Therapeutic Use
  • Acronyms RAP; Vienna-RAP-Study
  • Most Recent Events

    • 01 Jan 2015 Trial design presented at Trials.
    • 26 May 2014 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000550-60).
    • 08 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top